FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912143634> ?p ?o ?g. }

• W2912143634 endingPage "900" @default.
• W2912143634 startingPage "893" @default.
• W2912143634 abstract "Abstract Background The prognostic and predictive value of the two nonluminal (human epidermal growth factor receptor 2 [HER2]-enriched and basal-like) subtypes within advanced hormone receptor-positive (HR+) breast cancer is currently unknown. Materials and Methods This study retrospectively analyzed 261 tumors (80.7% primary; 19.3% metastatic) from the BOLERO-2 study; BOLERO-2 randomized 724 patients with advanced HR+/HER2-negative breast cancer to everolimus plus exemestane or placebo plus exemestane. Tumors were classified using a PAM50 subtype predictor. Multivariable Cox regression analyses tested the independent prognostic significance of PAM50, and associations between PAM50 subtypes and treatment upon progression-free survival (PFS) were evaluated. Results Subtype distribution was 46.7% luminal A (n = 122), 21.5% HER2-enriched (n = 56), 15.7% luminal B (n = 41), 14.2% normal-like (n = 37), and 1.9% basal-like (n = 5); HER2-enriched subtypes were more common in metastatic versus primary tumors (32.0% vs. 18.7%; p = .038). Median PFS differences between luminal and nonluminal (6.7 vs. 5.2 months; adjusted hazard ratio, 0.66; 95% confidence interval [CI], 0.47–0.94; p = .020) and HER2-enriched and non-HER2-enriched subtypes (5.2 vs. 6.2 months; adjusted hazard ratio, 1.53; 95% CI, 1.07–2.19; p = .019) were significant. Everolimus plus exemestane significantly improved median PFS versus placebo plus exemestane among patients with HER2-enriched tumors (5.8 vs. 4.1 months; adjusted hazard ratio, 0.49; 95% CI, 0.26–0.90; p = .034); however, the association between HER2-enriched tumors and everolimus benefit was nonsignificant (p = .433). Conclusion The HER2-enriched subtype was identified in a substantial proportion of advanced HR+/HER2-negative breast tumors, and was a consistent biomarker of poor prognosis. Tailored therapies are therefore needed for HER2-enriched tumors in the advanced HR+/HER2-negative breast cancer setting." @default.
• W2912143634 created "2019-02-21" @default.
• W2912143634 creator A5004300577 @default.
• W2912143634 creator A5004725639 @default.
• W2912143634 creator A5006511628 @default.
• W2912143634 creator A5013671018 @default.
• W2912143634 creator A5018616517 @default.
• W2912143634 creator A5018617106 @default.
• W2912143634 creator A5019569585 @default.
• W2912143634 creator A5043895722 @default.
• W2912143634 creator A5059201728 @default.
• W2912143634 creator A5061522111 @default.
• W2912143634 creator A5077805370 @default.
• W2912143634 creator A5081053376 @default.
• W2912143634 creator A5089513581 @default.
• W2912143634 date "2019-01-24" @default.
• W2912143634 modified "2023-10-17" @default.
• W2912143634 title "Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2" @default.
• W2912143634 cites W1861759122 @default.
• W2912143634 cites W2000881757 @default.
• W2912143634 cites W2031131661 @default.
• W2912143634 cites W2062071674 @default.
• W2912143634 cites W2088299041 @default.
• W2912143634 cites W2113458582 @default.
• W2912143634 cites W2121917721 @default.
• W2912143634 cites W2132619562 @default.
• W2912143634 cites W2135696440 @default.
• W2912143634 cites W2141414987 @default.
• W2912143634 cites W2144442992 @default.
• W2912143634 cites W2153061474 @default.
• W2912143634 cites W2166311434 @default.
• W2912143634 cites W2167188058 @default.
• W2912143634 cites W2208824773 @default.
• W2912143634 cites W2404884142 @default.
• W2912143634 cites W2414214572 @default.
• W2912143634 cites W2514365970 @default.
• W2912143634 cites W2560635244 @default.
• W2912143634 cites W2591810315 @default.
• W2912143634 cites W2757511999 @default.
• W2912143634 cites W2801511839 @default.
• W2912143634 doi "https://doi.org/10.1634/theoncologist.2018-0407" @default.
• W2912143634 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6656445" @default.
• W2912143634 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30679318" @default.
• W2912143634 hasPublicationYear "2019" @default.
• W2912143634 type Work @default.
• W2912143634 sameAs 2912143634 @default.
• W2912143634 citedByCount "22" @default.
• W2912143634 countsByYear W29121436342019 @default.
• W2912143634 countsByYear W29121436342020 @default.
• W2912143634 countsByYear W29121436342021 @default.
• W2912143634 countsByYear W29121436342022 @default.
• W2912143634 countsByYear W29121436342023 @default.
• W2912143634 crossrefType "journal-article" @default.
• W2912143634 hasAuthorship W2912143634A5004300577 @default.
• W2912143634 hasAuthorship W2912143634A5004725639 @default.
• W2912143634 hasAuthorship W2912143634A5006511628 @default.
• W2912143634 hasAuthorship W2912143634A5013671018 @default.
• W2912143634 hasAuthorship W2912143634A5018616517 @default.
• W2912143634 hasAuthorship W2912143634A5018617106 @default.
• W2912143634 hasAuthorship W2912143634A5019569585 @default.
• W2912143634 hasAuthorship W2912143634A5043895722 @default.
• W2912143634 hasAuthorship W2912143634A5059201728 @default.
• W2912143634 hasAuthorship W2912143634A5061522111 @default.
• W2912143634 hasAuthorship W2912143634A5077805370 @default.
• W2912143634 hasAuthorship W2912143634A5081053376 @default.
• W2912143634 hasAuthorship W2912143634A5089513581 @default.
• W2912143634 hasBestOaLocation W29121436341 @default.
• W2912143634 hasConcept C121608353 @default.
• W2912143634 hasConcept C126322002 @default.
• W2912143634 hasConcept C142724271 @default.
• W2912143634 hasConcept C143998085 @default.
• W2912143634 hasConcept C204787440 @default.
• W2912143634 hasConcept C207103383 @default.
• W2912143634 hasConcept C23589133 @default.
• W2912143634 hasConcept C27081682 @default.
• W2912143634 hasConcept C2775860665 @default.
• W2912143634 hasConcept C2775930923 @default.
• W2912143634 hasConcept C2776166826 @default.
• W2912143634 hasConcept C2779699572 @default.
• W2912143634 hasConcept C44249647 @default.
• W2912143634 hasConcept C50382708 @default.
• W2912143634 hasConcept C530470458 @default.
• W2912143634 hasConcept C71924100 @default.
• W2912143634 hasConceptScore W2912143634C121608353 @default.
• W2912143634 hasConceptScore W2912143634C126322002 @default.
• W2912143634 hasConceptScore W2912143634C142724271 @default.
• W2912143634 hasConceptScore W2912143634C143998085 @default.
• W2912143634 hasConceptScore W2912143634C204787440 @default.
• W2912143634 hasConceptScore W2912143634C207103383 @default.
• W2912143634 hasConceptScore W2912143634C23589133 @default.
• W2912143634 hasConceptScore W2912143634C27081682 @default.
• W2912143634 hasConceptScore W2912143634C2775860665 @default.
• W2912143634 hasConceptScore W2912143634C2775930923 @default.
• W2912143634 hasConceptScore W2912143634C2776166826 @default.
• W2912143634 hasConceptScore W2912143634C2779699572 @default.
• W2912143634 hasConceptScore W2912143634C44249647 @default.
• W2912143634 hasConceptScore W2912143634C50382708 @default.
• W2912143634 hasConceptScore W2912143634C530470458 @default.

• next